Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28780865 | 0.73 | LMNA (0.50) | CYP1A2CYP2C19NOS1DRD2ACHE | |
| SCHEMBL6845122 | 0.71 | CYP1A2 (0.56) | CYP1A2CYP2C19NOS1PBRM1PIK3CA | |
| SCHEMBL21026893 | 0.71 | GPR84 (0.39) | CYP1A2CYP2C19NOS1PBRM1GPR84 | |
| SCHEMBL20676148 | 0.71 | NOS1 (0.50) | CYP1A2CYP2C19NOS1GPR84DRD2 | |
| SCHEMBL24892249 | 0.71 | GRM4 (0.38) | PBRM1ILKMTORKDM4EALDH1A1 | |
| SCHEMBL17692468 | 0.70 | CYP1A2 (0.60) | CYP1A2CYP2C19NOS1DRD2SLC6A4 | |
| SCHEMBL18559460 | 0.69 | CYP1A2 (0.44) | CYP1A2CYP2C19NOS1DRD2SLC6A4 | |
| SCHEMBL21689940 | 0.68 | SLC7A5 (0.49) | CYP1A2NOS1AKT1KDM4EALDH1A1 | |
| SCHEMBL19852623 | 0.67 | CYP1A2 (0.42) | CYP1A2CYP2C19NOS1GPR84DRD2 | |
| SCHEMBL14217913 | 0.67 | ALDH1A1 (0.43) | CYP1A2CYP2C19NOS1GPR84DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108147-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-10954244-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | KALA BIO, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-9988386-B2 | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof | Kata Pharmaceuticals, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP1A2 3517/4885CYP2C19 1538/4885NOS1 43/4885 |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 3530/4885CYP2C19 2576/4885NOS1 3359/4885 |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | CYP1A2 3517/4885CYP2C19 1538/4885NOS1 43/4885 |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | CYP1A2 3701/4885CYP2C19 1787/4885NOS1 195/4885 |
| US-10954244-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | CYP1A2 3812/4885CYP2C19 1778/4885NOS1 155/4885 |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | CYP1A2 3517/4885CYP2C19 1538/4885NOS1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.